These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37410232)

  • 1. Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry.
    Park Y; Lelo A; Harris B; Berry DL; Chaldekas K; Kim JS; Waldman T
    Methods Mol Biol; 2023; 2684():145-151. PubMed ID: 37410232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
    Lelo A; Prip F; Harris BT; Solomon D; Berry DL; Chaldekas K; Kumar A; Simko J; Jensen JB; Bhattacharyya P; Mannion C; Kim JS; Philips G; Dyrskjøt L; Waldman T
    Clin Cancer Res; 2018 Sep; 24(17):4145-4153. PubMed ID: 29954776
    [No Abstract]   [Full Text] [Related]  

  • 3. STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.
    Taber A; Park Y; Lelo A; Prip F; Xiao J; Berry DL; Chaldekas K; Jensen JB; Philips G; Kim JS; Harris BT; Dyrskjøt L; Waldman T
    Urol Oncol; 2021 Jul; 39(7):438.e1-438.e9. PubMed ID: 33712344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent truncating mutations of STAG2 in bladder cancer.
    Solomon DA; Kim JS; Bondaruk J; Shariat SF; Wang ZF; Elkahloun AG; Ozawa T; Gerard J; Zhuang D; Zhang S; Navai N; Siefker-Radtke A; Phillips JJ; Robinson BD; Rubin MA; Volkmer B; Hautmann R; Küfer R; Hogendoorn PC; Netto G; Theodorescu D; James CD; Czerniak B; Miettinen M; Waldman T
    Nat Genet; 2013 Dec; 45(12):1428-30. PubMed ID: 24121789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes.
    Taylor CF; Platt FM; Hurst CD; Thygesen HH; Knowles MA
    Hum Mol Genet; 2014 Apr; 23(8):1964-74. PubMed ID: 24270882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of STAG2 in bladder cancer.
    Aquila L; Ohm J; Woloszynska-Read A
    Pharmacol Res; 2018 May; 131():143-149. PubMed ID: 29501732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAG2 expression is associated with adverse survival outcomes and regulates cell phenotype in muscle-invasive bladder cancer.
    Athans S; Krishnan N; Ramakrishnan S; Cortes Gomez E; Lage-Vickers S; Rak M; Kazmierczak Z; Ohm J; Attwood K; Wang J; Woloszynska A
    Cancer Res Commun; 2022 Oct; 2(10):1129-1143. PubMed ID: 36275363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
    Balbás-Martínez C; Sagrera A; Carrillo-de-Santa-Pau E; Earl J; Márquez M; Vazquez M; Lapi E; Castro-Giner F; Beltran S; Bayés M; Carrato A; Cigudosa JC; Domínguez O; Gut M; Herranz J; Juanpere N; Kogevinas M; Langa X; López-Knowles E; Lorente JA; Lloreta J; Pisano DG; Richart L; Rico D; Salgado RN; Tardón A; Chanock S; Heath S; Valencia A; Losada A; Gut I; Malats N; Real FX
    Nat Genet; 2013 Dec; 45(12):1464-9. PubMed ID: 24121791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer.
    Boegemann M; Krabbe LM
    Mini Rev Med Chem; 2020; 20(12):1133-1152. PubMed ID: 27173513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer.
    Qiao Y; Zhu X; Li A; Yang S; Zhang J
    Tumour Biol; 2016 Aug; 37(8):10279-86. PubMed ID: 26838030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stromal antigen 2 functions as a tumor suppressor in bladder cancer cells.
    Wang H; Zhong J; Wu C; Liu Y; Zhang J; Zou X; Chen Y; Su J; Yang G; Zhong Y; Tang A
    Oncol Rep; 2017 Aug; 38(2):917-925. PubMed ID: 28627627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of SAM68 in the progression and prognosis for bladder cancer.
    Zhang Z; Yu C; Li Y; Jiang L; Zhou F
    BMC Cancer; 2015 May; 15():364. PubMed ID: 25944080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of STAG2 causes aneuploidy in normal human bladder cells.
    Li X; Zhang TW; Tang JL; Fa PP; Lu JX; Qi FM; Cai ZM; Liu CX; Sun XJ
    Genet Mol Res; 2015 Mar; 14(1):2638-46. PubMed ID: 25867412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAG2 loss-of-function affects short-range genomic contacts and modulates the basal-luminal transcriptional program of bladder cancer cells.
    Richart L; Lapi E; Pancaldi V; Cuenca-Ardura M; Pau EC; Madrid-Mencía M; Neyret-Kahn H; Radvanyi F; Rodríguez JA; Cuartero Y; Serra F; Le Dily F; Valencia A; Marti-Renom MA; Real FX
    Nucleic Acids Res; 2021 Nov; 49(19):11005-11021. PubMed ID: 34648034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene mutation detection of urinary sediment cells for NMIBC early diagnose and prediction of NMIBC relapse after surgery.
    Zhu F; Zhang Y; Shi L; Wu CL; Chen SQ; Zheng H; Song DK
    Medicine (Baltimore); 2019 Aug; 98(32):e16451. PubMed ID: 31393349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.
    Le Goux C; Vacher S; Schnitzler A; Barry Delongchamps N; Zerbib M; Peyromaure M; Sibony M; Allory Y; Bieche I; Damotte D; Pignot G
    Sci Rep; 2020 Oct; 10(1):16641. PubMed ID: 33024200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAG2 Protein Expression in Non-muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes.
    Gordon NS; Humayun-Zakaria N; Goel A; Abbotts B; Zeegers MP; Cheng KK; James ND; Arnold R; Bryan RT; Ward DG
    Eur Urol Open Sci; 2022 Apr; 38():88-95. PubMed ID: 35495284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression.
    Piao XM; You C; Byun YJ; Kang HW; Noh J; Lee J; Lee HY; Kim K; Kim WT; Yun SJ; Lee SC; Kang K; Kim YJ
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of TAp63γ and P53 point mutations in regulating DNA repair, mutational susceptibility and invasion of bladder cancer cells.
    Wang HT; Lee HW; Weng MW; Liu Y; Huang WC; Lepor H; Wu XR; Tang MS
    Elife; 2021 Nov; 10():. PubMed ID: 34747697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.